Literature DB >> 6419012

Analysis of plasma lipids and apolipoproteins in insulin-dependent and noninsulin-dependent diabetics.

E R Briones, S J Mao, P J Palumbo, W M O'Fallon, W Chenoweth, B A Kottke.   

Abstract

Plasma triglycerides, cholesterol, high-density lipoprotein (HDL) cholesterol, and apolipoproteins (apo) A-I, A-II, C-II, and C-III were determined and analyzed in 170 diabetic patients and 46 age-matched healthy normal subjects. The diabetics were separated into two groups: insulin-dependent diabetes mellitus (IDDM, n = 78) and noninsulin-dependent diabetes mellitus (NIDDM, n = 92). Significantly increased triglycerides, low HDL cholesterol, and normal cholesterol levels were found in the diabetics. The lipid profiles were similar in the IDDM and NIDDM groups. Plasma apo A-I, but not apo A-II, was low in both groups of diabetics. However, only in the IDDM subjects was there a statistically significant decrease in apo A-I when compared to normal subjects. The decreased apo A-I level negatively correlated with plasma triglycerides. Apo C-II and apo C-III were slightly increased in the diabetics compared to normal subjects. Apo C-II and apo C-III levels significantly correlated with plasma triglycerides (apo C-II, r = 0.70, P less than 0.0001; apo C-III, r = 0.71, P less than 0.0001). Only apo C-II correlated with total cholesterol. Thirty-eight to forty-two percent of the IDDM and NIDDM subjects had a clinical diagnosis of coronary artery disease (CAD) and/or peripheral arteriovascular disease (PAD). In the IDDM subjects, but not in the NIDDM subjects the incidence of CAD and/or PAD was associated with the decreased apo A-I levels as evaluated by a univariate analysis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6419012     DOI: 10.1016/0026-0495(84)90160-4

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  17 in total

Review 1.  Lipoprotein alterations in diabetes mellitus.

Authors:  G M Kostner; I Karádi
Journal:  Diabetologia       Date:  1988-10       Impact factor: 10.122

2.  Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes.

Authors:  Anne Hiukka; Jamila Fruchart-Najib; Eeva Leinonen; Hannele Hilden; Jean-Charles Fruchart; Marja-Riitta Taskinen
Journal:  Diabetologia       Date:  2005-04-30       Impact factor: 10.122

Review 3.  Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease.

Authors:  Alison B Kohan
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-04       Impact factor: 3.243

4.  Featured Article: Oxidative stress status and liver tissue defenses in diabetic rats during intensive subcutaneous insulin therapy.

Authors:  Stéphanie Dal; Nathalie Jeandidier; Elodie Seyfritz; William Bietiger; Claude Péronet; François Moreau; Michel Pinget; Elisa Maillard; Séverine Sigrist
Journal:  Exp Biol Med (Maywood)       Date:  2015-09-18

5.  Chronic hyperprolactinemia and plasma lipids in women.

Authors:  H M Heshmati; G Turpin; J L de Gennes
Journal:  Klin Wochenschr       Date:  1987-06-01

6.  Lipoprotein compositional abnormalities in type 1 (insulin-dependent) diabetic patients.

Authors:  E Manzato; A Zambon; S Zambon; R Nosadini; A Doria; R Marin; G Crepaldi
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

Review 7.  Diabetic dyslipidaemia: from basic research to clinical practice.

Authors:  M-R Taskinen
Journal:  Diabetologia       Date:  2003-05-28       Impact factor: 10.122

Review 8.  Dietary protein and atherogenesis.

Authors:  C A Barth; M Pfeuffer
Journal:  Klin Wochenschr       Date:  1988-02-15

9.  Plasma lipoproteins and apolipoproteins in insulin-dependent and young non-insulin-dependent Arab women.

Authors:  N al-Muhtaseb; A R al-Yuosuf; J S Bajaj
Journal:  Acta Diabetol Lat       Date:  1991 Jan-Mar

10.  Role of MAPK in apolipoprotein CIII-induced apoptosis in INS-1E cells.

Authors:  E-ri M Sol; Tea Sundsten; Peter Bergsten
Journal:  Lipids Health Dis       Date:  2009-02-05       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.